Dr. Sy Pretorius has been appointed chief scientific officer at PAREXEL, in addition to his current role as the company’s corporate vice president and worldwide head of Early Phase.   Dr. Pretorius will lead innovation efforts for clinical research methodologies and help further integrate the company’s drug development services. He will focus on clinical trial modeling and simulations, adaptive trial designs, and will lead the company’s study optimization services by aligning its sci...